MedPath

Effect of Punarnavadi Kwath and Varunadi Kwath In The Management Of Mutravaha Sarotodushti ( Chronic Kidney Disesase )

Phase 2/3
Not yet recruiting
Conditions
Chronic kidney disease (CKD). Ayurveda Condition: MUTRAVAHASROTODUSHTIH,
Registration Number
CTRI/2021/04/033218
Lead Sponsor
National Institute Ayurveda Jaipur
Brief Summary

AIMSAND OBJECTIVES:

qTo evaluate and compare the clinicalefficacy of “Punarnavadi Kwatha†and “Varunadi Kwatha†in the management of Mutravaha Srotodushti w.s.r to Chronic Kidney Disease.

NEED OFSTUDY:

qRetarding the progression of renalfailure is one of the most important task of the nephrologist as it not onlyinvolves the quality of life of patient but also delays the development of endstage renal diseases, use of dialysis, transplantation cause financial burdento patient.

q Varunadi Kwatha seem to be helpful to relieve the Kapha and Vata Dosha and Punarnavadi Kwatha has Rasayan properties for Mutravaha Srotas which can prevent and repaired a tissuedamage.

q After reviewing the literature andkeeping in mind the Dosha- Dushya of Mutravaha Srotodusti, Punarnavadi Kwath and Varunadi Kwatha has been chosen for the study as thesedrugs possess above mentioned properties.



HYPOTHESIS:

NULLHYPOTHESIS:

There is nosignificance difference between the effect of trial drug ( PunarnavadiKwathand Varunadi Kwath)

ALTERNATIVEHYPOTHESIS:

There is a significant difference between theeffect of trial drugs (Punarnavadi Kwathand Varunadi Kwatha)in  the managementof Mutravaha Srotodushti.

STUDYDRUGS

A.PunaranavadiKwath( KalpitYoga )

B.VarunadiKwath( BhavaprakashaChi.37/12 )

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

1 Patient willing to participate in clinical trial 2 Patients having any clinical signs and symptoms of chronic renal failure 3 Patients with Hypertension <160/100 mm of hg 4 Patients of Serum creatinine level 1.2 to 5.0 mg/dl 5 Patients of Blood urea level 40 to 150 mg/dl.

Exclusion Criteria
  • 1 Age: below 21 years and above 59 years 2 Patients having other associated disease like congenital disease Myeloma, Neoplasm etc.
  • 3 Patient participated in any clinical trial with in last six months.
  • 4 Pregnant or lactating women.
  • 5 Familial or hereditary kidney disease, e.g. Polycystic kidney.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes in the clinical symptoms of Mutravaha Srotodushti (Chronic Kidney Disease).30 Days
Secondary Outcome Measures
NameTimeMethod
Changes in the objective parameters.30 Days

Trial Locations

Locations (1)

National Institute of Ayurveda and Hospital

🇮🇳

Jaipur, RAJASTHAN, India

National Institute of Ayurveda and Hospital
🇮🇳Jaipur, RAJASTHAN, India
Dr Karan Prakash Sharma
Principal investigator
8239225104
kpsayurvedh024@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.